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Abstract: 24 
Toxoplasma gondii, an intracellular parasitic protozoan, is capable of infecting man and all 25 
warm blooded animals. Cell-mediated immunity is vital in mounting protective responses 26 
against T. gondii infection. Recent studies have shown that T-helper (Th) 17 responses may 27 
play a key role in parasite control. In this current study, we constructed a DNA vaccine 28 
encoding T. gondii ROP13 in a pcDNA vector. Groups of BALB/c mice were immunized 29 
intramuscularly with pcROP13 or controls and challenged with the RH strain of T. gondii. 30 
The results showed that immunization with pcROP13 could elicit an antibody response 31 
against T. gondii. The expression of the canonical Th17 cytokines, IL-17 and IL-22, were 32 
significantly increased after immunization with pcROP13 compared to control groups 33 
(P<0.05). Furthermore, vaccination resulted in a significant decrease in parasite load 34 
(P<0.05). The induction of Th17 related cytokines, using a ROP13 DNA vaccine, against T. 35 
gondii should be considered as a potential vaccine approach for the control of toxoplasmosis.  36 
 37 
 38 
 39 
 40 
Keywords: ROP13, Toxoplasma gondii, Th17, IL-22, IL-17, DNA vaccine, Gene Expression  41 
 42 
 43 
3 
 
1. Introduction 44 
Toxoplasmosis is globally widespread parasitic infection caused by the intracellular 45 
protozoan pathogen, T. gondii, infecting humans and the other warm-blooded animals [1]. In 46 
immunocompetent people Toxoplasma infection is benign and mostly presents with no 47 
clinical manifestations. However, dependent on the status of host immune system it can cause 48 
serious and irreversible effects [1-2]. Toxoplasmosis in immunocompromised individuals is 49 
an opportunistic infection that may cause severe ocular and life-threatening neurological 50 
disorders [2]. Due to the high prevalence of T. gondii and the resulting pathogenesis of 51 
infection it is considered as a public health hazard. Despite extensive research, effective anti-52 
Toxoplasma therapeutics without side effects remains a barren area [3]. Hence, the most 53 
effective strategy to reduce disease burden and clinical outcomes is the development of 54 
vaccine formulations against T. gondii [4]. 55 
Current approaches to immunization against Toxoplasma infection takes several forms 56 
including attenuated live vaccines, killed vaccines and subunit vaccines [4-5]. Owing to the 57 
safety issues with the use of attenuated or killed forms of the pathogen, subunit vaccines have 58 
attracted considerable attention [4, 6]. In particular, DNA vaccines have been developed in 59 
recent years [5]. Results from several studies have raised the possibility of developing a DNA 60 
vectored vaccine to protect against T. gondii infection. The most investigated compounds as 61 
vaccine candidates include excreted-secreted antigens (ESA) and surface antigens of 62 
tachyzoites [7-9]. Previous findings indicate that ESA play a significant role in disease 63 
pathogenesis, and escape of the parasite from host immunity [10]. In particular Rhoptries 64 
(ROP) are unique secretory organelles that involved in host cell penetration by T. gondii and 65 
parasitophorous vacuole formation allowing survival and multiplication [11-12].  66 
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The protective mechanisms against T. gondii involve both CD4+ and CD8+ T-cell responses 67 
[13]. IFN-γ is known to be the major effector as a result of T-helper 1 (Th1) cell and NK cell 68 
activation. Th17 cells are a subset of CD4+ T-cells conditioned to produce the cytokines IL-69 
17, IL-21, and IL-22 which trigger responses causing the elimination of infection [13-16]. 70 
However, T cell-dependent production of IL-17 has been implicated in both protective and 71 
pathogenic responses during infection with T. gondii [17]. Subsequent studies identified NK 72 
cells as the innate IL-17 secreting cells in mice challenged with Toxoplasma [17-18]. 73 
Moreover, IL-17 mediated signaling was reported to play an important role during the initial 74 
stages of T. gondii infection through neutrophil recruitment and activation [19].  75 
Given the essential roles of ROP proteins in the pathogenesis of the Toxoplasma infection, 76 
these critical antigens are appropriate vaccine candidates [20]. ROP13 is a relatively recently 77 
recognized antigen of T. gondii and in tandem few studies have evaluated the Th17 response 78 
in T. gondii DNA vaccine [21]. Hence, the two major objectives of the present study was to 79 
construct a DNA vaccine vector expressing T. gondii ROP13 for use in immunization and to 80 
thereafter analyze the protective immune responses induced by vaccination and challenge 81 
with T. gondii RH strain.  82 
2. Materials and methods 83 
2.1 Mice and parasite 84 
 The highly virulent RH strain of T. gondii (type I) was used in all experiments. The RH 85 
tachyzoites were provided by Toxoplasmosis Research Center in Mazandaran University of 86 
Medical Sciences, Sari, Iran. The parasite was maintained by serial passage and 87 
intraperitoneal inoculation and female 6 to 8 week-old BALB/c mice. The animals were 88 
obtained from the Pasteur Institute of Iran and maintained under standard conventional 89 
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conditions. The animal experiments were approved by the local Ethics Committee of Tabriz 90 
University of Medical Sciences, Tabriz, Iran (No. IR.TBZMED.REC.1395.578).  91 
2.2 Cloning of ROP13 and construction of plasmids 92 
 DNA was extracted from tachyzoites by using an AccuPrep genomic DNA extraction kit 93 
(Bioneer, Korea) according to the manufacturer’s instructions. The NCBI GenBank database 94 
was used to determine the complete sequence of ROP13 gene of RH strain and to design 95 
specific primers (GeneBank accession number: JN051278.1).  The ROP13 gene was 96 
amplified using the primer pair Forward: 5' -GGATCCATGAAGAGAACAGAGCTTTG- 3', 97 
and Reverse: 5' -TCTAGATCACAATAGCCTCAAGGAATTC- 3' with six base pair, 98 
underlined, recognition sites for Bam HI and Xba I respectively in the primers. The coding 99 
sequence of ROP13 gene was 1203bp in length which was inspected by using 1% agarose gel 100 
electrophoresis to ensure the fidelity of the PCR product. The ROP13 PCR product was then 101 
inserted into the linearized pTG19-T vector (Vivantis) between the Bam HI and Xba I sites.  102 
The pTROP13 plasmid was then transferred into competent Top10 E. coli cells. Transformed 103 
bacteria were plated on LB-agar plates containing ampicillin, X-gal, and IPTG and incubated 104 
overnight. Blue/white screening was used to select transformed colonies harboring pTROP13 105 
were isolated and subjected to PCR to confirm the correct insertion was present [21-22]. 106 
To generate the vaccine plasmid pTROP13 was recovered from E. coli and subject to 107 
miniprep plasmid extraction (Gene All). The ROP13 coding sequence removed from the 108 
vector by double digestion cleavage using BamHI / XbaI (Jena Bioscience). The coding 109 
sequence was subject to gel purification and extraction (Bioneer, AccuPrep® Gel Purification 110 
Kit) before confirmation by DNA sequencing. To construct the vaccine vector, the ROP13 111 
gene sequence was ligated into the pcDNA3, yielded the plasmid pcROP13. 112 
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2.5 Transfection of CHO cells 113 
Chinese Hamster Ovary (CHO) cells were transfected with the pcROP13 plasmid. Cells, 1-2 114 
× 104 per well were plated into a 96-well tissue culture plate and used when the cells were 50-115 
80% confluent. Transfection was performed using jetPrime (Polyplus, France) according to 116 
the manufacturer’s instructions. Uptake of pcROP13 and expression from pcROP13 was 117 
detected 24-48 hours after transfection by immunofluorescence [21]. 118 
2.6 In vitro expression of pcROP13 119 
PcROP13 plasmid expression was detected by indirect immunofluorescence assay. Serial 120 
dilutions, beginning at 1/10, of the human anti-T. gondii antiserum were applied to 121 
transfected cells. Anti-sera were coated on a slide where the Transfected cells, on slides, were 122 
fixed, followed by incubation with anti-sera in a humidified chamber for 30 minutes; slides 123 
were then washed with PBS and dried at room temperature. The slides were subsequently 124 
incubated with secondary antibody of goat anti-human IgG conjugated with fluorescein 125 
isothiocyanate (FITC) for 30 minutes in the dark. After washing 3 times with PBS, the cells 126 
were mounted using buffered glycerol and examined for fluorescence detection under 127 
CYTATION5 imaging reader [21]. 128 
2.7 Mice immunization and challenge 129 
 Forty female 6-8-week-old BALB/c mice were divided into four groups; group A was 130 
vaccinated with 100 μg of pcROP13 DNA plasmid suspended in PBS, by intramuscular 131 
injection. Group B received PBS, Group C received empty pcDNA3 vector in PBS, and 132 
Group D received 20 μg of TLA (T. gondii lysate antigen). All mice were immunized three 133 
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times, two weeks apart prior to parasite challenge. Animals were infected with T. gondii RH 134 
strain by intraperitoneal injection with 1×104 parasites.  135 
2.8 Immune responses and determination of parasite load 136 
Serum IgG antibody levels were determined by ELISA as previously described (REF). 137 
Samples were obtained from mice at two individual time points including the pre-vaccination 138 
period (day 0) and on day 42 after immunization but prior to infection.  139 
To evaluate parasite load 3 days after challenge, DNA was extracted from the blood using the 140 
Blood Genomic DNA Extraction kit (YTA, Iran, Cat No: YT9040) according to the 141 
manufacturer’s instructions. Parasite load was determined by quantification of tachyzoites 142 
using real time PCR amplification of the highly conserved RE gene of T. gondii as previously 143 
described [23-24]. Briefly, forward primer: 5`AGGGACAGAAGTCGAAGGGG-3` and 144 
reverse primer: 5`GCAGCCAAGCCGGAAACATC-3` specified to amplify a 164-bp 145 
fragment of the RE gene using SYBR green chemistry, with all amplifications in triplicate. 146 
Q-PCR was performed using the following thermal cycling protocol: 10 minutes at 95°C, 40 147 
cycles at 94°C for 30 seconds (denaturation), 55°C for 30 seconds (annealing) and 72°C for 148 
30 seconds (amplification). Melting curve analysis was performed to verify the correct gene 149 
product ensuring the absence of side products. The threshold cycle (CT) value at which the 150 
fluorescence passes the fixed threshold was used to calculate the number of parasites in the 151 
samples according to a standard curve obtained with tachyzoites prepared for DNA samples 152 
over a range of 5 × 106 to 5 × 101/ml. The results were reported as T. gondii tachyzoite-153 
equivalents per ml of blood.  154 
Th17 cytokine gene expression was monitored using blood samples collected from 155 
animals  156 
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Subsequently, the blood RNA was extracted (YTA, Iran, Cat No: YT9075) and cDNA was 157 
synthesized (YTA, Iran, Cat No: YT4500) Real-time PCR for IL-17, IL-22 and GAPDH (as 158 
internal control) was performed using SYBR Green chemistry (YTA, Iran) on a Roche Real-159 
time PCR system (Applied Biosystems). The primers for IL-17 and IL-22 based on real-time 160 
PCR were as follow: IL-17 Forward primer: TCTCTGATGCTGTTGCTGCT, IL-17 Reverse 161 
primer: CGTGGAACGGTTGAGGTAGT, IL-22 Forward primer: 162 
TTGAGGTGTCCAACTTCCAGCA, IL-22 Reverse primer: 163 
AGCCGGACGTCTGTGTTGTTA. The PCR cycling was carried out in a final volume of 20 164 
µl reaction by an initial denaturation step at 95˚C for 3 min followed by 45 cycles at 95∘C for 165 
10 seconds, 58∘C for 30 seconds, and 72˚C for 20 seconds. Relative mRNA expression was 166 
measured by the 2-(ΔΔCT) method, using GAPDH as a reference gene.  167 
 2.11 Statistical analysis 168 
Statistical analysis was performed using GraphPad Prism 5.0 (San Diego, CA). Multiple 169 
comparisons between groups were conducted by 1-way ANOVA with post-hoc testing. P < 170 
0.05 was reported to be statistically significant. 171 
 3. Results 172 
3.1 Vaccine Construct 173 
The total DNA extracted from Toxoplasma tachyzoites and the coding sequence of ROP13 174 
gene was amplified using PCR, a 1203-bp PCR product corresponding to the ROP13 coding 175 
sequence was obtained (Figure 1A). This was inserted into the expression vector pcDNA3 176 
between the Bam HI and Xba I cloning sites. The pcROP13 was transferred into CHO cells 177 
and the protein expression was confirmed using IFAT (Figure. 1). 178 
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 180 
 181 
Figure 1. (Left) Gel electrophoresis analysis on PCR product, Lane 1: DNA size marker, Lane 2: 182 
ROP13 gene with the expected band size. Lane 3: negative control. (Right) Indirect 183 
immunofluorescence (IFA) detection of Toxoplasma gondii ROP13 on CHO cells (A: cells were 184 
transfected with pcROP13, B: empty vector).  185 
3.2 Immunization with pcROP13 186 
Groups of BALB/c mice were immunized with pcROP13 or appropriate controls.  187 
Immunization resulted in the seroconversion of animals as determined by ELISA.  A specific 188 
antibody response in both TLA and pcROP13 immunized groups was detected after the third 189 
immunization (Figure 2). The total IgG levels for both groups was significantly different 190 
(P<0.05) when compared to the negative control groups (PBS and pcDNA3).  191 
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 192 
Figure 2. Measurement of the specific anti-Toxoplasma IgG antbody in the sera of 193 
BALB/c mice before (left) and after (right) immunization at a 1:100 dilution.  The results 194 
are shown as mean of the OD450 ± SD of three independent experiments. *P < 0.05 195 
Statistically significant differences compared to control group were determined by a 1-196 
way anova. There were no detectable antibodies against T. gondii in the sera of control 197 
groups. 198 
 199 
3.3 Blood Cytokine mRNA expression 200 
48hr after the third immunization peripheral blood was collected from tail vein to evaluate the 201 
expression level of Th17 cytokines. The expression level of IL-22 mRNA in pcROP13 and 202 
TLA groups was found to be respectively 4 and nearly 2.5 folds higher than that observed in 203 
PBS and pcDNA3 groups (Figure 3). The expression of IL-17 was also significantly elevated 204 
among pcROP13 and TLA groups (2.8 and nearly 2 folds, respectively) compared with 205 
negative controls (P<0.05).  206 
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 207 
Figure 3. Relative mRNA expression of IL-17 (A) and IL-22 (B) in immunized mice with pcROP13, 208 
TLA, pcDNA3 and PBS. Results are expressed as mean and SD. P-value was determined using 1-way 209 
anova analysis (*P<0.05, ** P<0.01, *** P<0.001). 210 
3.4 Determination of parasite load in immunized mice 211 
To determine the protective efficacy of the pcROP13 vaccine to induce protection against T. 212 
gondii, immunized mice were challenged via the intraperitoneal route with 1 × 10 4 213 
tachyzoites 2 weeks after the third immunization. Blood parasite load was then determined by 214 
qPCR three days after challenge. Figure 4 clearly shows that immunization with either TLA 215 
or pcROP13 induced protection in mice as measured by the significantly different parasite 216 
burden (P<0.05). The PBS and pcDNA groups harbored on average 22201 and 18436 217 
parasite/mL, respectively. The pcROP13 and TLA immunized groups harbored 1694 and 812 218 
parasites, respectively. However no significant difference was observed between pcROP13 219 
and TLA groups (Figure 4). 220 
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 221 
Figure 4: The parasite load, tachyzoites/mL of blood in immunized mice following a 3-day i.p. 222 
infection with RH strain of T. gondii. Significant differences in parasite load between groups was 223 
detected by 1-way anova (*P < 0.05). 224 
4. Discussion 225 
Immunization with T. gondii ROP13 gene has been previously shown to induce a strong 226 
protective humoral and cellular response against infection in the recent study when 227 
adjuvanted with IL-18 [21]. In the current study, we constructed a vaccine plasmid pcROP13 228 
expressing protein ROP13 of T. gondii and evaluated the immune response induced in 229 
BALB/c mice. Our findings demonstrated that in addition to the induction of a humoral 230 
response, there is also an increased gene expression of Th17 cytokines (IL-17 and IL-22). In 231 
agreement with previous studies we found that immunization with pcROP13, as a DNA 232 
vaccine, successfully decreased the parasite load of blood in immunized mice.  233 
In the past decade, DNA vaccines have been widely studied and have been shown to elicit an 234 
efficient immune response against target antigens in various animal models [5, 25]. Various 235 
antigens of T. gondii have been assessed as potential candidates for vaccine development [8, 236 
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22, 26-27]. Rhoptries are found in apical secretory organelle and function in the 237 
establishment of infection through formation of specific compartments known as 238 
parasitophorous vacuoles in which parasite evades intracellular killing [11]. ROP13 is a 239 
unique soluble effector protein known to implicate in host cell invasion that can be detected 240 
in the cytoplasm of host cells [21]. A previous study evaluated the immunogenicity of a DNA 241 
vaccine expressing ROP13 of T. gondii, pVAX-ROP13, in Kunming mice. The pVAX-242 
ROP13 could induce humoral and cellular immunity against T. gondii [21]. The mice were 243 
assessed for production of cytokines specific for Th1 (IFN-γ and IL-2) and Th2 (IL-4 and IL-244 
10) after immunization and the results showed that the protective efficacy of the DNA 245 
vaccine expressing T. gondii ROP13 were related to Th1-driven immune response in 246 
Kunming mice, confirming the importance of the cellular immune response. 247 
Elimination of intracellular parasites is mainly conferred by Th1 immunity leading to the 248 
secretion of cytokines interferon-gamma (IFN-𝛾), interleukin-12 (IL-12) and tumor necrosis 249 
factor-alpha (TNF-𝛼) [16, 18]. IL17-producing T cells termed Th17 cells secrete a set of anti-250 
microbial cytokines including IL-22 and IL-21 and also mediate host protection against 251 
parasites and other pathogens [28-29]. They are involved in immunity to intracellular 252 
infections including Cryptosporidium, Plasmodium spp. and Trypanosoma cruzi [30-31]. 253 
However, pathogenic roles of Th17 responses have also been reported in the context of some 254 
parasitic infections [30, 32]. Among the complex network of cytokines that have been 255 
described in the immune responses to T. gondii, the pro-inflammatory cytokine, IFN-γ was 256 
shown to block intracellular development of the parasite and is considered as the main 257 
mediator of resistance to T. gondii [33]. There is evidence indicating that IL-22 has anti-258 
parasite effects during infection with intracellular parasite, Eimeria falciformis that belongs to 259 
the same phylum with T. gondii [34]. In contrast with these findings, IL-22 but not IL-17 is 260 
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shown to drive inflammation and tissue injury following mice infection with T. gondii [35]. 261 
Furthermore, recently published data from a mouse model of rickettsial infection, an obligate 262 
intracellular bacterium, demonstrates that either Th1 or Th17 responses can have protective 263 
effects. Surprisingly cells producing IL-17A or IL-22 are as protective as IFN-γ producing 264 
Th1 cells, if the immunopathologic effects of TNF-α are controlled [36]. This compliments 265 
recent novel findings that Th17 cells provide stronger protection, compared with Th1 266 
responses, against the intracellular microorganism T. cruzi [32]. These findings open the 267 
possibility that Th17 mediated protection during T. gondii is a prospect for vaccination. 268 
In the present study, we found significantly raised levels of both IL-17 and IL-22 mRNA in 269 
mice immunized with pcROP13 compared with control mice immediately prior to infection. 270 
These elevated levels of IL-17 and IL-22 in pcROP13 immunized mice associated with lower 271 
parasite burdens (P< 0.05) compared with PBS and pcDNA3 treated mice. This set of 272 
responses also provoked secretion of specific IgG antibodies detected in the sera of mice 273 
immunized with pcROP13 after the last immunization compared to control groups (P<0.05). 274 
Early reports supporting our data indicating a key role for IL-17 in the recruitment of 275 
neutrophils which is required for resistance to T. gondii [37]. Neutrophils are critical for 276 
successful host protection during early T. gondii infection [38]and experimental models have 277 
demonstrated that IL-17R-/- mice show significantly decreased migration of neutrophils into 278 
the peritoneal cavity after T. gondii infection [19], indicating that neutrophil response is 279 
dependent on IL-17-induced signaling. Studies on the NK response demonstrated that the 280 
need for Il-6 in driving IL-17 responses against T. gondii was conserved between across the 281 
T-cell populations [17]. 282 
In contrast to the perception that Th17 cells only function against extracellular pathogens, we 283 
have demonstrated that Th17 effectors, IL-17 and IL-22, may be important in the defense 284 
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against T. gondii infection as conferred by a ROP13 DNA-based vaccine. Multiple subtypes 285 
of innate and adaptive immune cells such as NK cells, γδ and CD4 T cells have been found as 286 
a source of IL-17; what subset of IL-17 producers is specifically implicated in pathogenic or 287 
protective immunity to T. gondii remained unclear. Further research is required to achieve a 288 
more detailed understanding of the exact correlates of protection against T. gondii infection in 289 
our system. This may enable us to revise the previously described harmful effects of IL-17 290 
and IL-22 producing T cells during infection with intracellular pathogens in particular T. 291 
gondii infection. 292 
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